- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Alkem Labs Gets USFDA Warning Letter for Daman Plant Earlier Classified OAI

Mumbai: Alkem Laboratories Limited has received a warning letter from the United States Food and Drug Administration (USFDA) concerning observations identified during an inspection of its manufacturing facility located at Amaliya, Daman, conducted between April 20 and May 1, 2026.
The company has stated that it will respond to the USFDA within the stipulated timeline and continues to manufacture and supply approved products from the facility to the US market.
The warning letter was issued on November 18, 2026, following the inspection, which had earlier been classified by the USFDA as Official Action Indicated (OAI). Alkem Laboratories had previously informed the stock exchanges about the inspection through communications dated May 2, 2026, and August 6, 2026.
The warning letter pertains to observations made by the USFDA during the inspection of the company's Amaliya manufacturing facility. The observations require Alkem Laboratories to implement appropriate corrective and preventive actions (CAPA) to address the identified deficiencies and prevent their recurrence.
The company has confirmed that it will submit its response to the USFDA within the prescribed timeline. Meanwhile, manufacturing and supply of approved pharmaceutical products from the Amaliya facility to the US market are continuing.
The development comes as Alkem Laboratories continues to operate its pharmaceutical manufacturing and international business across multiple markets. Established in 1973 and headquartered in Mumbai, the company is an Indian multinational pharmaceutical organisation engaged in the development, manufacturing and marketing of pharmaceutical products. Its business portfolio includes branded generics, generic medicines, active pharmaceutical ingredients (APIs), nutraceuticals and biosimilars.
Alkem Laboratories has a presence in more than 40 countries, with a portfolio of over 800 brands covering various therapeutic segments. Its pharmaceutical offerings include products across acute and chronic treatment areas, including anti-infectives, cardiovascular diseases, diabetes, respiratory disorders, gastroenterology, pain management and women's healthcare.
The company's manufacturing network comprises facilities in India and the United States, supported by research and development infrastructure focused on pharmaceutical formulations, product development and innovation. Its manufacturing capabilities cover multiple dosage forms, including tablets, capsules, injectables, dry syrups, oral liquids and other pharmaceutical formulations. The company also operates research facilities and has a team of scientists engaged in developing pharmaceutical products and strengthening its product pipeline.
Alkem Laboratories has established its presence in the US pharmaceutical market through the supply of pharmaceutical products across various therapeutic categories. The United States remains an important international market for the company, making its manufacturing and regulatory compliance activities significant to its overseas operations.
Alkem Laboratories has clarified that the USFDA warning letter will have no material impact on its current operations, financial position or other business activities.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

